CA3192661A1 - Anti-hla-dq2.5 antibody and its use for the treatment of celiac disease - Google Patents
Anti-hla-dq2.5 antibody and its use for the treatment of celiac diseaseInfo
- Publication number
- CA3192661A1 CA3192661A1 CA3192661A CA3192661A CA3192661A1 CA 3192661 A1 CA3192661 A1 CA 3192661A1 CA 3192661 A CA3192661 A CA 3192661A CA 3192661 A CA3192661 A CA 3192661A CA 3192661 A1 CA3192661 A1 CA 3192661A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- cdr
- amino acid
- variable region
- antibody variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020157873 | 2020-09-18 | ||
| JP2020-157873 | 2020-09-18 | ||
| PCT/JP2021/034240 WO2022059766A1 (en) | 2020-09-18 | 2021-09-17 | Anti-hla-dq2.5 antibody and its use for the treatment of celiac disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3192661A1 true CA3192661A1 (en) | 2022-03-24 |
Family
ID=80739984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3192661A Pending CA3192661A1 (en) | 2020-09-18 | 2021-09-17 | Anti-hla-dq2.5 antibody and its use for the treatment of celiac disease |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11739153B2 (https=) |
| EP (1) | EP4214236A4 (https=) |
| JP (2) | JP7147030B2 (https=) |
| KR (2) | KR20230116942A (https=) |
| CN (3) | CN117801114A (https=) |
| AR (1) | AR123537A1 (https=) |
| AU (2) | AU2021343008B2 (https=) |
| CA (1) | CA3192661A1 (https=) |
| CL (1) | CL2023000765A1 (https=) |
| CO (1) | CO2023003681A2 (https=) |
| CR (1) | CR20230166A (https=) |
| IL (1) | IL301326A (https=) |
| MX (1) | MX2023002191A (https=) |
| PE (1) | PE20231208A1 (https=) |
| TW (2) | TW202402804A (https=) |
| WO (1) | WO2022059766A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220153847A1 (en) * | 2019-04-01 | 2022-05-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-hla-dq2.5 antibody |
| JP7147030B2 (ja) * | 2020-09-18 | 2022-10-04 | 中外製薬株式会社 | 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用 |
| US20240400693A1 (en) * | 2021-10-08 | 2024-12-05 | Chugai Seiyaku Kabushiki Kaisha | Drug formulation of anti-hla-dq2.5 antibody |
| TW202333781A (zh) * | 2021-10-08 | 2023-09-01 | 日商中外製藥股份有限公司 | 抗ｈｌａ－ｄｑ２﹒５抗體製劑 |
| WO2026044027A1 (en) * | 2024-08-20 | 2026-02-26 | Victor Raso | Major histocompatibility complex peptides as therapeutic targets for autoimmune diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| IL158342A0 (en) | 2001-04-12 | 2004-05-12 | Academisch Ziekenhuis Leiden | Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides |
| EP2249801A2 (en) | 2008-02-07 | 2010-11-17 | Amgen Inc. | Stabilized protein compositions |
| AU2013204429B9 (en) | 2008-11-30 | 2017-01-05 | Immusant, Inc. | Compositions and methods for treatment of celiac disease |
| WO2010141658A1 (en) | 2009-06-04 | 2010-12-09 | The Regent Of The University Of Colorado | Therapeutic compositions and methods for the prevention of autoimmune diseases |
| CA2805564A1 (en) | 2010-08-05 | 2012-02-09 | Stefan Jenewein | Anti-mhc antibody anti-viral cytokine fusion protein |
| CN104011207B (zh) * | 2011-10-31 | 2018-09-18 | 中外制药株式会社 | 控制了重链与轻链的缔合的抗原结合分子 |
| WO2016202805A2 (en) | 2015-06-15 | 2016-12-22 | Consejo Superior De Investigaciones Científicas (Csic) | Targeting of prolamin by rnai in bread wheat |
| WO2017184880A1 (en) | 2016-04-20 | 2017-10-26 | Coherus Biosciences, Inc. | A method of filling a container with no headspace |
| JP7162607B2 (ja) * | 2017-02-27 | 2022-10-28 | 中外製薬株式会社 | 抗ｈｌａ－ｄｑ２．５／８抗体およびセリアック病の治療のためのその使用 |
| EP3692072A4 (en) | 2017-10-03 | 2021-12-22 | Chugai Seiyaku Kabushiki Kaisha | ANTI-HLA-DQ2.5 ANTIBODIES |
| GB201802338D0 (en) * | 2018-02-13 | 2018-03-28 | Univ Oslo | Antigen binding proteins |
| US20220153847A1 (en) | 2019-04-01 | 2022-05-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-hla-dq2.5 antibody |
| JP7147030B2 (ja) | 2020-09-18 | 2022-10-04 | 中外製薬株式会社 | 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用 |
-
2021
- 2021-09-17 JP JP2021151709A patent/JP7147030B2/ja active Active
- 2021-09-17 KR KR1020237024631A patent/KR20230116942A/ko active Pending
- 2021-09-17 TW TW112137009A patent/TW202402804A/zh unknown
- 2021-09-17 IL IL301326A patent/IL301326A/en unknown
- 2021-09-17 CA CA3192661A patent/CA3192661A1/en active Pending
- 2021-09-17 CN CN202311813323.8A patent/CN117801114A/zh active Pending
- 2021-09-17 MX MX2023002191A patent/MX2023002191A/es unknown
- 2021-09-17 US US17/477,651 patent/US11739153B2/en active Active
- 2021-09-17 EP EP21869449.5A patent/EP4214236A4/en active Pending
- 2021-09-17 CR CR20230166A patent/CR20230166A/es unknown
- 2021-09-17 KR KR1020217042982A patent/KR102559128B1/ko active Active
- 2021-09-17 WO PCT/JP2021/034240 patent/WO2022059766A1/en not_active Ceased
- 2021-09-17 AR ARP210102585A patent/AR123537A1/es unknown
- 2021-09-17 CN CN202311818773.6A patent/CN117801115A/zh active Pending
- 2021-09-17 CN CN202180061976.8A patent/CN116096757B/zh active Active
- 2021-09-17 TW TW110134821A patent/TWI820484B/zh active
- 2021-09-17 PE PE2023001173A patent/PE20231208A1/es unknown
- 2021-09-17 AU AU2021343008A patent/AU2021343008B2/en active Active
-
2022
- 2022-09-02 JP JP2022139889A patent/JP7840234B2/ja active Active
-
2023
- 2023-03-16 CL CL2023000765A patent/CL2023000765A1/es unknown
- 2023-03-23 CO CONC2023/0003681A patent/CO2023003681A2/es unknown
- 2023-07-05 US US18/346,975 patent/US20230357408A1/en active Pending
-
2026
- 2026-01-22 AU AU2026200463A patent/AU2026200463A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR123537A1 (es) | 2022-12-14 |
| JP2022051553A (ja) | 2022-03-31 |
| AU2021343008B2 (en) | 2025-11-13 |
| JP7840234B2 (ja) | 2026-04-03 |
| CN117801115A (zh) | 2024-04-02 |
| EP4214236A1 (en) | 2023-07-26 |
| US20220089743A1 (en) | 2022-03-24 |
| CN116096757A (zh) | 2023-05-09 |
| WO2022059766A1 (en) | 2022-03-24 |
| TWI820484B (zh) | 2023-11-01 |
| US11739153B2 (en) | 2023-08-29 |
| KR102559128B1 (ko) | 2023-07-24 |
| US20230357408A1 (en) | 2023-11-09 |
| MX2023002191A (es) | 2023-03-03 |
| JP7147030B2 (ja) | 2022-10-04 |
| AU2021343008A1 (en) | 2023-06-01 |
| AU2026200463A1 (en) | 2026-02-12 |
| EP4214236A4 (en) | 2024-10-30 |
| KR20220153469A (ko) | 2022-11-18 |
| IL301326A (en) | 2023-05-01 |
| CN117801114A (zh) | 2024-04-02 |
| JP2022172276A (ja) | 2022-11-15 |
| AU2021343008A9 (en) | 2024-10-10 |
| CO2023003681A2 (es) | 2023-04-05 |
| PE20231208A1 (es) | 2023-08-17 |
| TW202229345A (zh) | 2022-08-01 |
| TW202402804A (zh) | 2024-01-16 |
| KR20230116942A (ko) | 2023-08-04 |
| CL2023000765A1 (es) | 2023-11-03 |
| CR20230166A (es) | 2023-05-31 |
| CN116096757B (zh) | 2024-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11739153B2 (en) | Anti-HLA-DQ2.5 antibody and its use for the treatment of celiac disease | |
| WO2021131021A1 (ja) | 抗ｃｔｌａ－４抗体およびその使用 | |
| JP7689495B2 (ja) | 抗ｈｌａ－ｄｑ２．５抗体 | |
| TW202333781A (zh) | 抗ｈｌａ－ｄｑ２﹒５抗體製劑 | |
| US20240400693A1 (en) | Drug formulation of anti-hla-dq2.5 antibody | |
| EA052398B1 (ru) | Антитело к hla-dq2.5 и его применение для лечения глютеновой энтеропатии | |
| HK40084713A (en) | Anti-hla-dq2.5 antibody and its use for the treatment of celiac disease | |
| HK40101674A (zh) | 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途 | |
| HK40101688A (zh) | 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途 | |
| HK40084713B (zh) | 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途 | |
| HK40062978B (zh) | 抗hla-dq2.5抗体 | |
| HK40062978A (en) | Anti-hla-dq2.5 antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240910 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240910 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240910 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250815 |
|
| D16 | Fast track examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D16-D108 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION REQUESTED - PPH Effective date: 20250815 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250815 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250815 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250818 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250818 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250818 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250818 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250818 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250818 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250827 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250908 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250908 |
|
| D17 | Fast track examination accepted |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D17-D112 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION DETERMINED COMPLIANT - PPH Effective date: 20250910 |
|
| D17 | Fast track examination accepted |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D17-D161 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PPH RETAINED AFTER REVIEW Effective date: 20250915 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D141 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CONDITIONAL ALLOWANCE Effective date: 20251202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251202 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D163 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO CONDITIONAL NOTICE OF ALLOWANCE Effective date: 20260122 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20260129 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260129 |